---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040700"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:51:07.524020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q3 revenue $41.1M (+99% YoY); raises FY2022 guidance to $145M

## Summary
- Q3 revenue $41.1M (+99% YoY from $20.7M); gross profit $9.7M vs $0.4M; net loss $14.9M ($0.08 loss/share) narrowing from $17.7M.
- FY2022 revenue guidance raised to ~$145M from prior $130M; reiterates profitability target no later than Q1 2024.
- ASCENIV record pull-through; ongoing strategic review with Morgan Stanley; BioCenters on track for 10 FDA-licensed centers by 2023.
- Long-term targets: revenue $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.

## SEC filing metadata
- accession: 0001140361-22-040700
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/0001140361-22-040700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/brhc10043955_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040700
- JSON: https://secwatch.observer/filing/0001140361-22-040700.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040700.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported the three months ended September 30, 2022 results: revenue $41.1 million. Guidance raised.
  - Period: the three months ended September 30, 2022
  - Revenue: $41.1 million
  - Guidance: raised
  - Result: reported results
  source text: 2 brhc10043955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036122040700/0001140361-22-040700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.